| You are here: Home: BCU 8|2003: Leroy M Parker, MD: Select publications
Select Publications
Publications discussed by Dr Parker
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract Erratum in: J Clin Oncol 2003;21(11):2226.
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 35.
Steger GG et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc ASCO 2003;Abstract 78.
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial: Efficacy and safety update analyses. Cancer 2003;98:1802-10. Abstract
Vergote I et al. Postmenopausal women who progress on fulvestrant (‘Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract
Watanabe T et al. Fulvestrant provides clinical benefit to postmenopausal women with metastatic breast cancer who have relapsed on prior antiestrogen therapy: A Japanese study. Proc ASCO 2003;Abstract 274.
Evaluation of flavopiridol's role in solid tumors
Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000;6(4):379-92. Abstract
Chen ZS et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63(14):4048-54. Abstract
Gries J-M et al. Phase I study of flavopiridol 24 hour infusion monotherapy in solid tumors (HMR1275/1002). Proc ASCO 2003;Abstract 564.
Li Y et al. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 2000;6(1):223-9. Abstract
Li Y et al. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 2000;17(4):755-9. Abstract
Lu K et al. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol 2000;46(4):293-304. Abstract
Nahta R et al. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003;63(13):3626-31. Abstract
Nahta R et al. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002;62(8):2267-71. Abstract
Nahta R et al. Signal transduction inhibitors in the treatment of breast cancer. Curr Med Chem Anti-Canc Agents 2003;3(3):201-16. Abstract
|
